...
机译:每周预防40 IU / kg NonacogβPEGOL(N9-GP)达到血友病患者患者的槽水平> 15%:来自范式的汇集数据? 审判
Institute of Experimental Haematology and Transfusion MedicineUniversity Clinic BonnBonn Germany;
Division of Haematology/Oncology Department of Paediatrics and Research Institute Hospital for;
Department of Internal Medicine Carver College of MedicineUniversity of IowaIowa City Iowa;
Haemophilia Comprehensive Care Centre Faculty of Health SciencesNHLS and University of the;
Angelo Bianchi Bonomi Haemophilia and Thrombosis CentreFondazione IRCCS Ca' Granda Ospedale;
Department of Transfusion MedicineNagoya University HospitalNagoya Japan;
Haemophilia and Thrombosis Centre Louis Pradel HospitalUniversity Claude BernardLyon France;
Novo Nordisk A/SS?borg Denmark;
Novo Nordisk A/SS?borg Denmark;
Hemostasis and Thrombosis Center Children's Hospital Los AngelesUniversity of Southern California;
factor IX; haemophilia B; nonacog beta pegol; prophylaxis; target joint; trough level;
机译:每周预防40 IU / kg NonacogβPEGOL(N9-GP)达到血友病患者患者的槽水平> 15%:来自范式的汇集数据? 审判
机译:乙型血友病中的Nonacogβ聚乙二醇(N9-GP):一项多国III期安全性和有效性扩展试验(范例(TM)4)
机译:在NonacogβPEGOL(N9-GP)的每次预防治疗中,儿童和成人达到稳态血浆浓度的聚乙二醇(PEG)。
机译:基于范式7比较药代动力学研究的Nonacogβ聚乙二醇(N9-GP)和rFIXFc的按需和外科手术的人群药代动力学模型
机译:每周预防40 IU / kg NonacogβPEGOL(N9-GP)达到血友病患者患者的槽水平> 15%:来自PARADIGM™试验的汇集数据